Assembly Biosciences, Inc. (ASMB)

Every figure this model derived for ASMB, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 85,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 320,361,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 327,978,000 AssetsCurrent 2026-06-30
current liabilities 23,445,000 LiabilitiesCurrent 2026-06-30
equity 305,649,000 StockholdersEquity 2026-06-30
ocf -38,481,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 72,303,000 RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31
sbc 6,663,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ASMB on one particular measure came for.

RatioValue
cash operating margin-2.8
current ratio45.93
current ratio reported13.99
deferred revenue growth-60.15
dilution pct86.79
fcf margin-53.34
growth cv1.53
operating margin-12.17
owner earnings margin-62.55
revenue growth153.52
revenue growth per share35.73
rule of 40141.35
sbc pct revenue9.22

What to be careful about

What this model itself distrusts about ASMB's figures. Written by the derivation as it ran, not added afterwards.